Ford Megan, Thomson Paul J, Lister Adam, Snoeys Jan, Leclercq Laurent, Cuyckens Filip, Naisbitt Dean J, Meng Xiaoli
Department Pharmacology and Therapeutics, University of Liverpool, Liverpool L693GE, U.K.
Translational Pharmacokinetics Pharmacodynamics and Investigative Toxicology, Johnson & Johnson, 2340 Beerse, Belgium.
Chem Res Toxicol. 2025 May 19;38(5):812-815. doi: 10.1021/acs.chemrestox.5c00070. Epub 2025 May 6.
Exposure to atabecestat is associated with liver injury, which subsequently led to its withdrawal from development. Previous studies of patients with atabecestat induced liver injury identified T cells responsive to atabecestat and its metabolites, indicating that immune-mediated mechanisms are involved. As irreversible protein modification is suspected to drive immunogenicity, this study aimed to characterize potential atabecestat protein adducts using HSA, GSTA1, and GSTP as model proteins. We have shown that atabecestat only formed a cysteine adduct on GSTP in the presence of metabolic systems, highlighting the important role of bioactivation in adduct formation and selectivity for the binding interaction.
接触阿他贝司他与肝损伤有关,这随后导致其研发终止。先前对阿他贝司他诱导肝损伤患者的研究确定了对阿他贝司他及其代谢产物有反应的T细胞,表明免疫介导机制参与其中。由于怀疑不可逆的蛋白质修饰会驱动免疫原性,本研究旨在使用人血清白蛋白(HSA)、谷胱甘肽S-转移酶A1(GSTA1)和谷胱甘肽S-转移酶P(GSTP)作为模型蛋白来表征潜在的阿他贝司他蛋白加合物。我们已经表明,在代谢系统存在的情况下,阿他贝司他仅在GSTP上形成了半胱氨酸加合物,突出了生物活化在加合物形成中的重要作用以及结合相互作用的选择性。